| (Values in U.S. Thousands) | Jun, 2025 | Jun, 2024 | Jun, 2023 | Jun, 2022 | Jun, 2021 |
| Sales | 0 | 0 | 0 | 0 | 0 |
| Sales Growth | unch | unch | unch | unch | unch |
| Net Income | -3,580 | -4,300 | -5,870 | -7,450 | -1,350 |
| Net Income Growth | +16.74% | +26.75% | +21.21% | -451.85% | -66.67% |
Regencell Bioscience Holdings Ltd (RGC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Regencell Bioscience Holdings Limited is an early-stage bioscience company which focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. Regencell Bioscience Holdings Limited is based in HONG KONG.
Fiscal Year End Date: 06/30